This study is conducted in Asia. The aim of of this study is to evaluate the safety of
NovoPen® 3 and/or FlexPen® devices (if available on the market) measured by the number of
adverse events and technical complaints in patients with type 1 and type 2 diabetes in
routine clinical practice.